8-KLeadership Changes

PFIZER INC 8-K Report, Executive Changes (Mar 4, 2020)

Filed March 4, 2020For Securities:PFE

Summary

Pfizer Inc. (PFE) announced a significant addition to its Board of Directors with the election of Dr. Susan Hockfield, effective March 3, 2020. Dr. Hockfield's extensive experience in science and technology is expected to bolster the company's strategic direction, particularly given her appointments to the Regulatory and Compliance Committee and the Science and Technology Committee. This move signifies Pfizer's continued commitment to strengthening its leadership with individuals possessing deep scientific expertise, which is crucial for navigating the complex landscape of drug development and regulatory approval.

Key Highlights

  • 1Pfizer Inc. elected Dr. Susan Hockfield to its Board of Directors, effective March 3, 2020.
  • 2Dr. Hockfield's appointment strengthens the Board's scientific and technological expertise.
  • 3She has been appointed to the Regulatory and Compliance Committee.
  • 4She has also been appointed to the Science and Technology Committee.
  • 5Dr. Hockfield will receive compensation according to the company's standard non-employee director arrangements.
  • 6An indemnification agreement has been provided to Dr. Hockfield.
  • 7The announcement was made via a press release dated March 4, 2020, attached as an exhibit.

Frequently Asked Questions

Dr. Susan Hockfield is a distinguished figure with deep expertise in science and technology. Her election to the Board of Directors is significant as it enhances Pfizer's leadership's scientific and regulatory acumen, which is vital for the company's innovation pipeline and navigating complex global health challenges.

Dr. Hockfield has been elected to serve on two key committees of the Board: the Regulatory and Compliance Committee and the Science and Technology Committee.

Dr. Hockfield will be compensated in accordance with Pfizer's standard arrangements for its non-employee directors, and she has also been provided with an indemnification agreement.

Dr. Hockfield's election to the Board of Directors was effective immediately upon her election on March 3, 2020.